A new frontier in cancer treatment may be emerging—not through injections or surgery, but through something as simple as breathing. Recent developments highlighted by New Scientist report that the first-ever inhalable gene therapy for cancer has been fast-tracked by the U.S. Food and Drug Administration (FDA), marking a significant shift in how gene therapies can be delivered and applied.
The therapy, currently under investigation for lung cancer, works by delivering immune-boosting genes directly into lung cells via inhalation. Instead of circulating through the bloodstream like conventional treatments, the therapy is administered as a fine mist using a nebulizer. This allows it to act locally within the lungs—targeting tumours more directly and potentially reducing systemic side effects.
At the core of this innovation is a modified viral vector, engineered to safely transport genetic material into cells. Once inside, these genes instruct the cells to produce proteins—specifically immune signaling molecules—that help the body recognize and attack cancer. Early findings suggest that this approach can shrink tumours or stop their growth in some patients, particularly those who have exhausted other treatment options.
This therapy has received what is known as a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. This designation is reserved for treatments that show early promise in addressing serious or life-threatening conditions and allows for an accelerated development and review process.
One of the most compelling aspects of inhalable gene therapy is its precision. Traditional cancer treatments often struggle to reach sufficient concentrations in the lungs without affecting other parts of the body. By delivering therapy directly to the site of disease, this approach may enhance effectiveness while minimizing harm.
However, the science is still in its early stages. Initial trials have involved small patient groups, and while results are promising, larger clinical studies are needed to confirm safety, effectiveness, and long-term outcomes. Current research is also exploring how this therapy might work in combination with existing treatments such as chemotherapy and immunotherapy.
Beyond the immediate implications for lung cancer, this development signals a broader shift in biotechnology: moving from generalized treatment approaches to highly targeted, localized, and genetically informed interventions.
For regions like Africa, where access to advanced therapies remains uneven—this raises important questions about inclusion, infrastructure, and representation in genomic research. As gene-based therapies evolve, ensuring that diverse populations are included in research and data collection will be critical to making these innovations truly global.
At MyAfroDNA, this moment reinforces a core truth: the future of medicine is being written in our DNA. And who is represented in that data will determine who benefits from the breakthroughs ahead.
A new study from the University of Lausanne by is shedding light on how cancer cells adapt and survive, even under treatment pressure. The research uncovers a surprising role for vitamin B7 (biotin) in enabling cancer cells to switch metabolic pathways, a flexibility that may contribute to treatment resistance.
Cancer cells are known for their rapid growth, and to sustain this, many rely heavily on a nutrient called glutamine. This phenomenon, often described as “glutamine addiction” has made glutamine metabolism a key target in cancer therapy. However, treatments that block glutamine pathways don’t always work as expected. Tumors often find alternative ways to survive.
Researchers discovered that vitamin B7 acts as a critical cofactor for an enzyme called pyruvate carboxylase, which allows cancer cells to switch from glutamine dependency to another metabolic route. In simple terms, biotin enables cancer cells to “change fuel sources” when their primary supply is cut off.
When vitamin B7 was limited in controlled experimental conditions, this metabolic flexibility was disrupted. As a result, cancer cells were less able to adapt, and their growth was significantly reduced.
This finding points to a potential strategy in cancer treatment: instead of targeting a single metabolic pathway, therapies could be designed to block multiple survival routes simultaneously. By combining glutamine inhibition with disruption of biotin-dependent processes, researchers may be able to expose a key vulnerability in tumor cells.
The study also highlights the role of the FBXW7 gene, a known tumor suppressor. Mutations in this gene commonly observed in several cancer types appear to make cancer cells even more reliant on glutamine metabolism. This suggests that patients with such mutations could respond differently to therapies targeting metabolic pathways, reinforcing the importance of personalized medicine.
For African genomics and health research, these findings are particularly relevant. Understanding how genetic variations influence cancer metabolism is essential for developing treatments that are effective across diverse populations. It also underscores the need for more inclusive datasets in biomedical research.
While the study focuses on vitamin B7, it does not suggest that people should reduce their intake of biotin. This vitamin is essential for normal bodily functions, including energy metabolism and skin health. The findings are specific to controlled laboratory settings and targeted therapeutic strategies, not dietary recommendations.
Cancer’s strength lies in its ability to adapt. This research shows that vitamin-dependent metabolic pathways may be one of the mechanisms behind that adaptability, and a promising target for future treatments.
🔗 Read the full article:
https://www.sciencedaily.com/releases/2026/04/260420014744.htm
Source: ScienceDaily (University of Lausanne)
Lassa fever is a viral haemorrhagic disease endemic to West Africa, caused by the Lassa virus and primarily transmitted through exposure to food or surfaces contaminated by infected rodents. Human-to-human transmission can also occur, particularly in healthcare settings without adequate infection control. Symptoms range from mild fever and weakness to severe complications such as bleeding, organ failure, and, in some cases, death.
Nigeria continues to experience seasonal outbreaks, and recent data from the Nigeria Centre for Disease Control and Prevention shows that 2026 is following a concerning trajectory.
As of Epidemiological Week 8 (February 2026):
- 404 confirmed cases have been recorded
- 99 deaths, with a case fatality rate (CFR) of 24.5%
- Cases have spread across 18 states and 67 Local Government Areas
While weekly confirmed cases have slightly declined (77 new cases in Week 8 compared to 82 in Week 7), the rising fatality rate higher than 18.8% in 2025 signals ongoing gaps in early detection and treatment access.
More recent updates suggest the trend persists. By March 2026, Nigeria had recorded over 580 confirmed cases and more than 140 deaths, maintaining a high fatality rate above 24%.
Geographic and Demographic Trends
The outbreak remains highly concentrated:
- Bauchi (30%), Ondo (21%), and Taraba (19%) account for the majority of cases
- Together with Edo and Benue, these states contribute 84% of all confirmed infections
The most affected group is young adults aged 21–30, although cases span from infants to older adults. Men are slightly more affected than women (ratio 1:0.8).
Healthcare workers also remain at risk, with new infections recorded among frontline responders highlighting persistent vulnerabilities in infection prevention systems.
Treatment Gaps and a New Breakthrough
Currently, treatment options for Lassa fever are limited. The antiviral drug ribavirin is widely used but is most effective only when administered early, which is often not the case due to delayed diagnosis.
However, new research published in Nature introduces a promising development. Scientists have identified an oral antiviral drug, 4′-fluorouridine (4′-FIU), that demonstrated strong efficacy in treating Lassa fever in nonhuman primates.
Key findings from the study include:
- Effectiveness even when treatment begins several days after infection
- Significant reduction in viral load
- Improved survival outcomes
This is particularly important because Lassa fever is often diagnosed late, when existing treatments are less effective. An oral drug also offers practical advantages for deployment in rural and resource-limited settings.
What This Means for Public Health in Africa
The combination of rising fatality rates and continued geographic spread underscores the urgency of improving surveillance, diagnostics, and treatment access.
At the same time, advances like 4′-FIU highlight the role of genomics, antiviral research, and global collaboration in addressing endemic diseases.
While the drug is still in the experimental stage and requires human clinical trials, it represents a potential shift in how Lassa fever is treated especially in regions where early intervention is difficult.
Lassa fever remains a persistent and evolving public health challenge in Nigeria. But with improved data tracking and emerging therapeutic innovations, there is a clear pathway toward better outcomes and reduced mortality if investments in research, healthcare systems, and community awareness continue.
Read more on the Lassa fever trend in Nigeria .
A recent study in Nature Scientific Reports provides new insights into the genetic diversity of African populations and its implications for disease research and precision medicine. The research highlights how African genomes carry unique and medically relevant genetic variants, many of which are still underrepresented in global datasets.
One of the most important findings is the high variability of disease-associated genetic markers across African populations. For example, variants linked to protection against severe malaria, such as those in the G6PD gene, show significantly different frequencies across regions. Similarly, the well-known sickle cell mutation (HbS) appears at high frequencies in malaria-endemic regions of West and East Africa but is far less common in Southern Africa.
This variation is not random, it reflects centuries of evolutionary adaptation to environmental pressures such as infectious diseases. Another key example is the APOL1 gene variants, which are associated with increased risk of kidney disease. These variants are more common in parts of West Africa, illustrating how genetic adaptations that once provided survival advantages can also influence modern disease risk.
Why This Matters for Research and Medicine
These findings reinforce a critical gap in global health research: African populations remain underrepresented in genomic studies, despite having the highest genetic diversity worldwide. This lack of representation limits the ability to:
- Accurately identify disease risk factors
- Develop effective diagnostics
- Design targeted therapies
- Advance precision medicine
Without diverse biospecimens and genomic data, researchers risk building solutions that do not fully apply to African populations.
The Role of Biobanking and African-Led Research
To bridge this gap, the study underscores the importance of:
- Expanding genomic databases with African representation
- Strengthening biobanking systems for diverse biospecimens
- Supporting collaborative, African-led research initiatives
Biobanks play a central role by enabling the ethical collection, storage, and sharing of biological samples that reflect real population diversity.
At MyAfroDNA, we are committed to advancing inclusive genomic research by providing:
- Access to diverse African biospecimens
- Ethical biobanking and sample management
- Partnerships with researchers, institutions, and healthcare organizations
We invite researchers, universities, and public health institutions to collaborate with us in building datasets and research that truly reflect African populations.
Inclusive genomics is essential for equitable healthcare. Africa must be represented not approximated in global science.
Read more on this research at nature scientific.
Trusted DNA Testing Services in Nigeria
MyAfroDNA provides reliable and confidential DNA testing services in Nigeria for individuals, families, legal professionals, and institutions. Whether you need a paternity DNA test, immigration DNA test, or other relationship testing services, our process is handled with professionalism and strict laboratory standards.
We serve clients across Lagos, Abuja, Port Harcourt, Rivers State, and other cities nationwide.
If you are searching for where to get a DNA test done in Nigeria, MyAfroDNA offers trusted and accurate solutions.
Paternity DNA Testing in Nigeria
Our paternity DNA test determines biological fatherhood with over 99.99% accuracy. This service is available for:
- Peace-of-mind testing
- Legal and court-admissible testing
- Family confirmation purposes
Each test follows secure sample collection procedures and professional laboratory processing to ensure reliable and confidential results.
MyAfroDNA provides paternity DNA testing services across Nigeria with discretion and scientific precision.
Immigration & Legal DNA Testing
MyAfroDNA provides immigration DNA testing services for embassy and visa requirements. Our documentation process follows internationally recognized standards to ensure accurate and legally acceptable results.
We assist families and individuals throughout Nigeria who require DNA testing for official purposes.
Sibling & Relationship DNA Testing
In addition to paternity testing, we provide:
- Sibling DNA testing
- Maternity testing
- Grandparent DNA testing
- Other biological relationship verification services
All tests are conducted using scientifically validated procedures to ensure high levels of accuracy.
Why Choose MyAfroDNA for DNA Testing in Nigeria?
- Accurate and reliable DNA test results
- Strict confidentiality and data protection
- Nationwide service coverage
- Professional laboratory standards
- Efficient turnaround times
- Experienced scientific team
MyAfroDNA combines biotechnology expertise with accessible DNA testing services tailored to individuals and institutions across Nigeria.
DNA Testing Available Nationwide
We provide DNA testing services in:
- Port Harcourt
- Lagos
- Abuja
- Rivers State
- Other locations across Nigeria
If you are searching for “DNA test near me” in Nigeria, our team is available to guide you through the process professionally and confidentially.
Frequently Asked Questions
How much does a DNA test cost in Nigeria?
Our DNA Paternity test is the cheapest in Nigeria and costs 150,000 naira only. Additional charges may apply for shipment of samples or the type of test required. Contact MyAfroDNA directly for current pricing and consultation.
How long does a paternity DNA test take in Nigeria?
Our turnaround time is seven days and can be expedited in cases of emergencies. Our team provides clear timelines during bookings.
Is DNA testing confidential?
Yes. All DNA testing services at MyAfroDNA are handled with strict confidentiality and data protection standards.
Book a DNA Test in Nigeria
To schedule your DNA test appointment, contact MyAfroDNA today.
Call us on 07010644048
Or send us a WhatsApp message on 07010644048 to book an appointment
Our team will guide you through the process professionally and d
Recently, MyAfroDNA announced the acquisition of the CycloneSEQ sequencer nanopore genome sequencing platform, becoming the first facility in West Africa to deploy this advanced technology. This milestone represents a significant advancement for genome sequencing in Nigeria, biotechnology in West Africa, and African-led genomics research.
But what exactly is the CycloneSEQ platform? How does nanopore sequencing work? And why does this matter for researchers, institutions, and biotech organizations across Africa and globally?
In this article, we explain:
- What the CycloneSEQ platform does
- The science behind its enhanced protein engineering and flow cell design
- Its advantages over traditional sequencing systems
- Why long-read sequencing is critical for modern genomics
- How institutions can collaborate with MyAfroDNA
What Is the CycloneSEQ Nanopore Sequencing Platform?
The CycloneSEQ platform, including the CycloneSEQ-WT02 and CycloneSEQ-WY01 models, is an advanced nanopore-based genome sequencing system developed by MGI Tech Co., Ltd. Unlike conventional short-read sequencing platforms that fragment DNA into small pieces for computational assembly, nanopore sequencing reads long DNA molecules directly as they pass through nanoscale protein pores.
As DNA passes through each nanopore, changes in electrical current are detected at picoampere resolution. These signals are then decoded in real time using advanced basecalling algorithms.
This enables:
- Long-read genome sequencing
- Real-time data generation
- Structural variant detection
- Whole genome assembly
- Metagenomics and pathogen surveillance
- Agricultural and biodiversity genomics
For biotechnology in Nigeria and West Africa, this introduces a new level of sequencing capability previously unavailable locally.
Advanced Technology Behind CycloneSEQ
The CycloneSEQ platform integrates several major innovations that elevate its performance in genomic applications.
Enhanced Protein Engineering
CycloneSEQ utilizes:
- A high thermal stability motor protein
- A structurally rigid nanopore protein
This refined structure improves:
- DNA unwinding efficiency
- Nucleic acid capture
- Reduced sequencing noise
- Signal stability
These enhancements increase threading precision as DNA passes through the pore, significantly improving sequencing reliability.
High-Density Flow Cell Architecture
Each flow cell supports up to 4,096 nanopore protein sensors arranged in a high-density array.
The integration of:
- BioMEMS microfluidic control systems
- ASIC-based electronic signal processing
Allows ultra-sensitive detection of current changes at picoampere levels.
This enables:
- Stable, ultra-long sequencing runs
- High-throughput genomic analysis
- Multi-flow cell scalability
- Continuous real-time sequencing
Optimized Basecalling Algorithm (97% Accuracy)
CycloneSEQ employs a proprietary basecalling algorithm trained using large-scale distributed computing.
With reported accuracy rates of approximately 97%, the system delivers:
- Real-time DNA sequence decoding
- Reliable variant detection
- Reduced computational post-processing
- Improved structural variant resolution
This level of optimization is critical for clinical research, agricultural genomics, and biodiversity projects.
Innovative Nanopore Local Chemistry
A novel sequencing chemistry modulates magnesium ion electrophoretic migration to regulate motor protein activity.
This chemistry improves:
- DNA translocation control
- Sequencing efficiency
- Signal clarity
- Run stability
Together, these innovations position CycloneSEQ as a highly competitive long-read sequencing platform.
CycloneSEQ vs Traditional Sequencing Platforms
Understanding the distinction between long-read nanopore sequencing and traditional short-read systems is essential.
1. Read Length
Traditional platforms generate short DNA fragments requiring computational reassembly.
CycloneSEQ reads long continuous DNA strands, enabling more accurate genome assembly.
2. Structural Variant Detection
Short-read sequencing may struggle with:
- Large insertions
- Repeat expansions
- Complex rearrangements
Long-read sequencing excels in resolving these genomic features.
3. Infrastructure and Accessibility
Traditional systems often require:
- Large-scale laboratory infrastructure
- High capital investment
- Significant operational overhead
CycloneSEQ offers greater flexibility and accessibility for emerging genomics laboratories.
4. Turnaround Time
Outsourcing sequencing abroad can delay research timelines.
With local genome sequencing now available in Nigeria at MyAfroDNA, turnaround time is significantly reduced.
5. Data Sovereignty
Local sequencing strengthens data ownership and supports African-led genomics research initiatives.
Why This Matters for Biotechnology in Nigeria and Africa
Africa contains the highest human genetic diversity globally, yet remains underrepresented in genomic databases.
The deployment of West Africa’s first CycloneSEQ nanopore sequencer strengthens:
- Precision medicine research
- Agricultural biotechnology
- Crop genome assembly
- Pathogen genomics
- Biodiversity and conservation research
- Academic and institutional genomics programs
By expanding DNA sequencing services in Nigeria, MyAfroDNA contributes to positioning Africa as an active contributor, not just a participant, in global genomics.
Frequently Asked Questions
What is nanopore sequencing?
Nanopore sequencing reads DNA directly as it passes through a protein pore, detecting electrical current changes to determine sequence information.
Is CycloneSEQ suitable for whole-genome sequencing?
Yes. It supports long-read whole-genome assembly and structural variant analysis.
Who can partner with MyAfroDNA?
Universities, biotech startups, hospitals, agricultural institutes, NGOs, pharmaceutical researchers, and international collaborators.
Is this technology only for human genomics?
No. It supports plant, microbial, animal, environmental, and metagenomic sequencing applications.
How can organizations access this service?
Institutions can contact MyAfroDNA to discuss project scope, sample type, volume requirements, and turnaround expectations.
Partner with MyAfroDNA
Partner with West Africa’s first nanopore sequencing facility.
MyAfroDNA now offers advanced genome sequencing services in Nigeria, serving researchers and institutions across West Africa, Africa, and globally.
If your organization requires:
- Long-read genome sequencing
- Structural variant analysis
- Agricultural genomics
- Pathogen surveillance
- Biodiversity sequencing
- Precision medicine research support
Our team is ready to collaborate.
Contact MyAfroDNA today to discuss your sequencing project and explore how CycloneSEQ technology can support your research objectives.
Cancer research is entering a transformative era. Precision oncology, the approach of tailoring cancer treatments based on a patient’s unique genetic profile, is already revolutionizing care in many parts of the world. However, recent evidence underscores a critical gap: precision oncology in Africa cannot succeed without African‑centric genomic data, infrastructure, and research partnerships. (Nature Africa, 2026)
Many of the genomic datasets driving current precision oncology tools are largely derived from populations outside Africa. While these datasets have enabled breakthroughs in diagnostics, therapy selection, and prognostic assessments, they do not capture the full spectrum of genetic diversity found in African populations. This matters because cancer development, mutation patterns, and drug responses are influenced by ancestry-specific genomic variations. Without representative African data, treatments risk being less effective or missing critical mutation patterns prevalent in African patients.
Why African Genomes Are Essential for Precision Oncology
The Nature Africa feature emphasizes that African populations possess high genetic diversity, one of the richest in the world. This diversity affects not only susceptibility to certain cancer types but also the effectiveness of targeted therapies. For example, mutations in genes such as TP53, BRCA1/2, or EGFR may appear with different frequencies or impact drug responses differently in African patients compared to non-African populations. Precision oncology that ignores this variation risks exacerbating health disparities, rather than reducing them.
The Role of Biobanking and Genomic Research
To build effective precision oncology for Africa, robust biobanks and genomic infrastructure are vital. Biobanks store ethically collected biological samples — including blood, tissue, saliva, and DNA — under controlled conditions for research. They allow researchers to:
- Identify population-specific genetic variants
- Map tumor evolution in African patients
- Develop diagnostic assays tailored to local mutation patterns
- Support clinical trials that reflect real-world African populations
Ethical stewardship and consent are central to biobanking. Samples must be traceable, stored securely, and used transparently for approved research. African biobanks like MyAfroDNA aim to provide this foundation while supporting collaborations with hospitals, universities, and research institutions.
Investing in African Genomic Capacity
Precision oncology requires more than samples; it needs trained personnel, advanced sequencing technologies, molecular tumor boards, and data analysis capacity. African researchers and clinicians must be empowered to interpret genomic information in context, linking mutations to effective therapies. Collaborative networks allow the sharing of resources, expertise, and knowledge to accelerate the translation of genomic insights into patient care.
Partner With MyAfroDNA for Precision Oncology for Africans by Africans
At MyAfroDNA, we are committed to advancing African-centric precision oncology through:
- Ethical biospecimen collection and storage
- Access to diverse African genomic samples for research
- Partnerships with researchers, hospitals, and institutions
- Training programs in genomic analysis and precision medicine
We invite researchers, universities, hospitals, and pharmaceutical companies to collaborate with us. By working together, we can ensure that precision oncology in Africa is informed by representative genomic data, supports tailored therapies, and contributes to equitable healthcare outcomes.
African genomic research is not just a scientific opportunity; it is a responsibility. Every sample, study, and collaboration strengthens the foundation for cancer care that is designed by Africans, for Africans.
Partner with MyAfroDNA today to advance precision oncology and genomic research in Africa.
Source: Nature Africa — Precision oncology specifically for Africa (nature.com)
MyAfroDNA, an African biotechnology company focused on advancing genomics research and innovation on the African continent, has announced the acquisition and deployment of the MGI CycloneSEQ™ genome sequencer, becoming the first facility in West Africa to deploy this advanced, portable sequencing platform.
CycloneSEQ is a cost-efficient long-read sequencing platform suitable for generating high-quality reference genomes across diverse biological systems. Its accuracy, scalable throughput, and streamlined workflows support reliable genome sequencing, assembly, and variant resolution, enabling large-scale sequencing projects with reduced per-sample cost compared to conventional long-read approaches. The system’s compact footprint and stable operation make it appropriate for sustained deployment in African research environments, facilitating locally led genome projects while strengthening regional capacity and data stewardship.
Figure 1: Photo of recently acquired CycloneSEQ genome sequencer deployed at MyAfroDNA facility in Port Harcourt, Nigeria
The CycloneSEQ™ significantly strengthens MyAfroDNA’s capacity to perform high-resolution, high-accuracy genomic sequencing, enabling applications across human health, agriculture, biodiversity, and environmental research. This milestone marks a major step toward expanding Africa’s ability to generate and analyze genomic data locally, reducing reliance on external sequencing infrastructure.
“The acquisition of the CycloneSEQ™ genome sequencer significantly strengthens our ability to generate high-quality whole-genome data locally and at scale. It allows us to support research across health, agriculture, and biodiversity, while ensuring African-led projects are powered by African infrastructure, expertise, and data ownership,” said Dr. Justin Eze Ideozu, Founder of MyAfroDNA.
Designed for precision and scalability, the CycloneSEQ™ supports whole-genome sequencing, reference genome development, population genomics, and accurate detection of genetic variants. Its flexible workflows enable MyAfroDNA to support both targeted studies and large-scale genomic projects requiring high data quality.
As part of this deployment, MyAfroDNA will immediately begin generating high-quality reference genomes to support biodiversity and conservation genomics in partnership with the African BioGenome Project (AfricaBP) and the West Africa Regional Node of the AfricaBP, Regional Center for Biotechnology and Bioresources Research (RCBBR), University of Port Harcourt, Nigeria.
“The presence of CycloneSEQ™ at MyAfroDNA is a significant development which will certainly inject life into the Endangered and Endemic Species BioGenome Project of the West African Regional node of AfricaBP. It will, as well, facilitate realization of the AfricaBP-10KP 2.0 and AfricaBP Plant Genome Projects. Hopefully, our first genome sequence will be rolled out soon. I sincerely congratulate Dr Justin Eze Ideozu and MyAfroDNA for achieving this great milestone”, said Professor Julian Osuji, AfricaBP West Africa Regional Node Coordinator and Director of the Regional Center for Biotechnology and Bioresources Research (RCBBR), University of Port Harcourt, Nigeria.
“We are happy to see the CycloneSEQ™ deployed in West Africa with MyAfroDNA. This installation represents what MGI aims to achieve globally - democratizing access to advanced sequencing technologies. We look forward to supporting MyAfroDNA and AfricaBP in their mission to sequence Africa’s endemic species by placing high-accuracy long-read capabilities directly into the hands of African researchers", said Chen Fang, General Manager of MGI Europe and Africa.
“MyAfroDNA and MGI are two strong partners of the African BioGenome Project (AfricaBP) who have demonstrated strong commitments to the African genomics and molecular biology landscape. To sequence African indigenous and endemic biological species will require intentional investments by African organisations, and I’m quite pleased (and particularly proud) to see MyAfroDNA take this bold step in acquiring the portable CycloneSEQ genome sequencer. This is a testament to the AfricaBP ecosystem in enabling partnerships, collaborations, and local investments, adding to its progress of consistently provoking local actions. The AfricaBP cannot wait to kickstart its sequencing with MyAfroDNA, and supporting biodiversity genome sequencing in Africa”, said Dr. ThankGod Echezona Ebenezer, Founder and Co-Chair, AfricaBP.
This acquisition positions West Africa as an active contributor to global genomics and life sciences research. By enabling in-region sequencing, MyAfroDNA will support universities, research institutes, conservation organizations, biotechnology companies, and policymakers with access to advanced genomic infrastructure previously unavailable in the region.
This development reinforces MyAfroDNA’s broader mission to strengthen Africa’s biotechnology ecosystem and apply genomics to real-world challenges in health, agriculture, biodiversity conservation, and environmental sustainability.
About MyAfroDNA
We are an African biotechnology company that provides solutions to the significant lack of African representation in clinical, genomics, and translational research. Contact us for questions: info@myafrodna.com
A new study published in Nature projects that climate change, especially extreme weather events could lead to a substantial increase in malaria cases and deaths across Africa over the next 25 years.
Using 25 years of climate, health, socioeconomic, and disease control data, researchers estimate that climate change could contribute to up to 123 million additional malaria cases and more than 500,000 additional deaths between 2024 and 2050 if current control strategies remain unchanged.
While many studies have focused on how temperature and rainfall affect mosquito ecology, this research shows that extreme weather such as floods and cyclones — will be the main driver of increased risk, disrupting housing, health services, prevention programs, and access to treatment. These disruptions may account for the majority of additional cases and deaths in the coming decades.
Most of the projected increases will occur in regions where malaria is already endemic rather than in entirely new areas, underscoring the vulnerability of existing control systems to climate shocks. These findings highlight a profound challenge: climate change doesn’t just reshape environments, it can undermine disease control infrastructures, particularly where health systems are already fragile.
For genomic scientists and public health researchers, this study reinforces the urgency of climate-resilient malaria strategies that integrate environmental forecasting, vector surveillance, health system preparedness, and genomic research to track parasite and vector evolution under changing conditions.
At MyAfroDNA, we are committed to supporting collaborative research that advances:Climate-informed malaria surveillance Integrated vector genomics and environmental data systemsCommunity-embedded biospecimen collection and analysisData-driven intervention and control strategiesIf you are a researcher, institution, or organization working on malaria, climate health, genomics, or vector-borne disease research, we invite you to partner with MyAfroDNA. Together, we can develop solutions that are tailored to Africa’s climate and health needs.